|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that this protocol successfully decreases the expression of two key genes associated with AD, the triggering receptor expressed in myeloid cells 2 (TREM2) and CD33, in primary microglia cell cultures.
|
30297984 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The IGAP SNPs in ABCA7, CD2AP, and CD33 each acted as eQTL for AD-associated genes in brain.
|
30448613 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD33 is one of the top-ranked AD risk genes identified by genome-wide association studies.
|
30541012 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggested that the two CD33 common variants (rs3826656 and rs3865444) influenced volumes and atrophy rates of AD-related brain regions in non-demented elders.
|
30883353 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, integrating currently available findings leads us to propose a model wherein the CD33 isoform lacking the ligand-binding domain represents a gain of function variant that reduces Alzheimer's disease risk.
|
30949760 |
2019 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Results showed that Curc-lo decreased CD33 and increased TREM2 expression (predicted to decrease AD risk) and also increased TyroBP, which controls a neuroinflammatory gene network implicated in AD as well as phagocytosis markers CD68 and Arg1.
|
30951849 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The CD33 genotype associated cognitive performance was bidirectionally modulated by intrinsic functional connectivity in the Alzheimer's disease spectrum.
|
31054508 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SRSF1 and PTBP1 Are <i>trans</i>-Acting Factors That Suppress the Formation of a CD33 Splicing Isoform Linked to Alzheimer's Disease Risk.
|
31208978 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.
|
31301936 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
(2019) demonstrate opposing effects of CD33 and TREM2 on AD phenotypes, where CD33 deletion promotes neuroprotection in a manner dependent on TREM2.
|
31487521 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this article, we will illustrate the special challenges of AD drug discovery by discussing the viability/practicality of possible microglia drug targets including cluster of differentiation 33 (CD33), K<sub>Ca</sub>3.1, kynurenines, ionotropic P2 receptor 7 (P2X7), programmed death-1 (PD-1), Toll-like receptors (TLRs), and triggering receptor expressed in myeloid cells 2 (TREM2).
|
31507408 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multifaceted evidence supports the hypothesis that inflammatory-immune mechanisms contribute to Alzheimer disease (AD) neuropathology and genetic association of several immune specific genes (TREM2, CR1, and CD33) suggests that maladaptive immune responses may be pivotal drivers of AD pathogenesis.
|
31607776 |
2019 |